Genmab Further Validates its DuoBody™ Technology with Janssen Biotech Agreement
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 7 (Table of Contents)
Published: 25 Jul-2012
DOI: 10.3833/pdr.v2012.i7.1784 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Genmab has made further progress with its DuoBody™ technology platform by agreeing to collaborate with Johnson & Johnson’s Janssen Biotech to create and develop bispecific antibodies against multiple disease targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS